3 Houston innovators to know this week

who's who

This week's roundup of Houston innovators includes Atul Varadhachary of Fannin, Natasha Gorodetsky of Product Pursuits, and Jay Hartenbach of Diakonos Oncology. Photos courtesy

Editor's note: Every Monday, I'm introducing you to three Houston innovators to know — three individuals behind recent innovation and startup news stories in Houston as reported by InnovationMap. Learn more about them and their recent news below by clicking on each article.

Atul Varadhachary, managing director of Fannin Innovation

Atul Varadhachary of Fannin joins the Houston Innovators Podcast. Photo via LinkedIn

Commercializing a life science innovation that has the potential to enhance or even save the lives of millions of patients is a marathon, not a sprint. That's how Atul Varadhachary thinks of it, and he's leading an organization that's actively running that race for several different early-stage innovations.

For over a decade, Fannin has worked diligently to develop promising life science innovations — that start as just an idea or research subject — by garnering grant funding and using its team of expert product developers to build out the technology or treatment. The model is different from what you'd see at an accelerator or incubator, and it also varies from the path taken by an academic or research institution.

The life science innovation timeline is very different from a software startup's, which can get to an early prototype in less than a year.

"In biotech, to get to that minimally viable product, it can take a decade and tens of millions of dollars," Varadhachary, managing director at Fannin, says on the Houston Innovators Podcast. Read more.

Natasha Gorodetsky, founder and CEO of Product Pursuits

A product management expert shares how artificial intelligence is affecting the process for the tech and startup worlds. Photo via LinkedIn

For over a year, the tech and business community has been obsessing over artificial intelligence. As Natasha Gorodetsky, the Houston-based founder and CEO of Product Pursuits, writes in a guest column about how the product management community is not an exception.

"Product managers — as well as startup founders leading a product function — more than any other role, face a challenge of bringing new life-changing products to market that may or may not be received well by their users," she writes. "A product manager’s goal is complex — bring value, stay ahead of the competition, be innovative. Yet, the "behind the scenes" grind requires endless decision making and trade offs to inspire stakeholders to move forward and deliver."

She continues in her article to outline the trends of AI for product management. Read more.

Jay Hartenbach, COO of Diakonos Oncology

A Houston company with a promising immuno-oncology is one step closer to delivering its cancer-fighting drug to patients who need it. Photo via Diakonos

Diakonos Oncology has recently made major headway with the FDA, including both a fast track and an orphan drug designation. It will soon start a phase 2 trial of its promising cancer fighting innovation.

The therapy catalyzes a natural immune response, it’s the patient’s own body that’s fighting the cancer. Hartenbach credits Decker with the idea of educating dendritic cells to attack cancer, in this case, glioblastoma multiforme (GBM), one of the most aggressive cancers with which doctors and patients are forced to tangle.

“Our bodies are already very good at responding very quickly and aggressively to what it perceives as virally infected cells. And so what Dr. Decker did was basically trick the immune system by infecting these dendritic cells with the cancer specific protein and mRNA,” details COO Jay Hartenbach. Read more.

A Houston company with a promising immuno-oncology is one step closer to delivering its cancer-fighting drug to patients who need it. Photo via Getty Images

Houston immuno-oncology company reaches next FDA milestone, heads to phase 2 trial

green light

A Houston immuno-oncology company has recently made major headway with the FDA, including both a fast track and an orphan drug designation. It will soon start a phase 2 trial of its promising cancer fighting innovation.

Diakonos Oncology was born in 2016, the brainchild of Baylor researchers already hard at work in the realm of dendritic cell vaccines. Drs. Will Decker, Matt Halpert, and Vanaja Konduri partnered with Dan Faust, a Houston businessman and pharmacist, to bring their treatment to the public, says COO Jay Hartenbach.

The name Diakonos means “deacon or servant in Greek,” he explains. “A lot of companies end up focusing on treating a specific disease or cancer and what you end up having is a significant amount of potential but with a lot of tradeoffs and downsides. And so our goal is we need to eliminate the cancer but we can't harm or dramatically malign the patient in doing so.”

How do they do that? Because the therapy catalyzes a natural immune response, it’s the patient’s own body that’s fighting the cancer. Hartenbach credits Decker with the idea of educating dendritic cells to attack cancer, in this case, glioblastoma multiforme (GBM), one of the most aggressive cancers with which doctors and patients are forced to tangle.

“Our bodies are already very good at responding very quickly and aggressively to what it perceives as virally infected cells. And so what Dr. Decker did was basically trick the immune system by infecting these dendritic cells with the cancer specific protein and mRNA,” details Hartenbach.

Jay Hartenbach is the COO of Diakonos Oncology. Photo courtesy of Diakonos Oncology

But GBM isn’t the only cancer on which Diakonos Oncology has its sights set. Other notably stubborn-to-treat cancers that they’re working on include pancreatic cancer and angiosarcoma. The scientists are focused on meeting unmet medical needs, but also realize that treating such cancers would allow for the fastest determination of whether or not the treatment was effective.

The fast track designation, originally received last fall, means that the drug approval time for DOC1021, Diakonos’ glioblastoma vaccine, will be only six months. But Hartenbach highlights an additional boon, the fact that the special designation also allows for more frequent communications with the FDA.

“That’s very helpful for us, right as we're contemplating how to design the upcoming trials. From a business standpoint, it also is incredibly helpful because it provides a third party validation of what we're doing and the results that we're seeing,” he says.

What they’re seeing includes the survival of 13 out of 16 patients from the initial October 2021 enrollment. The three patients who passed away received the lowest dose of DOC1021. Hartenbach says that the remaining patients are thriving, with no serious adverse effects. With a median survival rate of 15 to 21 months, it’s hard to understate the significance of these patients’ success.

Diakonos Oncology is headquartered in Houston, with a staff of 10 in Space City and an additional eight distributed employees. Hartenbach says that the company’s hometown has been instrumental in its success. He mentions that the robust innovation of the Texas Medical Center meant that as the company has grown, there has never been a motivation to leave Houston.

“You're having a lot of both investment and companies actually moving to Houston,” Hartenbach says. “So we’ve been fortunate to have started there. There are bigger traditional biotech hubs, San Diego, Boston, and San Francisco, but Houston really is now putting itself on the map and it's getting a lot of attention.”

One of the companies responsible for that improved reputation? Diakonos Oncology and its promising approach to aggressive cancers.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston lab-test startup seeks $1M for nationwide expansion

Testing Access

Health care industry veteran Jim Gebhart knew there had to be a better way for patients to access lab services, especially those with high health insurance deductibles or no insurance at all.

“This challenge became deeply personal when a close family member developed a serious illness, and we struggled to secure prompt appointments,” Gebhart tells InnovationMap. “It’s incredibly frustrating when a loved one cannot receive timely care simply because of provider shortages or the limited capacity of traditional clinics.”

Driven by the desire to knock down lab-test barriers, Gebhart founded Houston-based TheLabCafe.com in 2024. The platform provides access to low-cost medical tests without requiring patients to carry health insurance. TheLabCafe serves patients in six states: Texas, Georgia, Louisiana, Nevada, New Mexico and Oklahoma. Gebhart, the startup’s CEO, says that by the end of March, LabCafe will be offering services in 20 more states and the District of Columbia.

Gebhart has spent more than 30 years in the lab industry. His career includes stints at Austin-based Clinical Pathology Laboratories, Ohio’s Cleveland Clinic Laboratories and Secaucus, New Jersey-based Quest Diagnostics.

“Since nearly 80 percent of disease diagnoses rely on laboratory testing, I decided to leverage my background to create a more accessible, self-directed process for individuals to order blood and urine tests on their own terms — when and where they need them,” says Gebhart.

So far, Gebhart is self-funding the startup. But he plans to seek $700,000 to $1 million in outside investments in late 2026 to support the nationwide expansion and the introduction of more services.

TheLabCafe contracts with labs for an array of tests, such as cholesterol, hepatitis, metabolic, testosterone, thyroid and sexually transmitted infection (STI) tests. A cholesterol test obtained through TheLabCafe might cost $29, compared with a typical cost of perhaps $39 to $59 without insurance.

A health care professional reviews every test, both when the test is ordered and when the results are delivered, often within 24 hours. After receiving test results, a patient can schedule a virtual visit with a health care professional to go over the findings and learn potential treatment options.

Gebhart says TheLabCafe particularly benefits uninsured patients, including those in Texas. Among the states, Texas has the highest rate of uninsured residents. U.S. Census Bureau data shows 21.6 percent of adults and 13.6 percent of children in Texas lacked health insurance in 2024.

“Uninsured patients often pay the highest prices in the health care system,” Gebhart explains. “We address this by offering straightforward pricing and convenient access to testing without requiring insurance.”

“Our rates are intentionally set to remain affordable, helping individuals take a proactive approach to their health,” he adds. “Regular testing enables people to identify potential health issues early and track their progress as they make lifestyle changes. Ultimately, you can’t measure improvement without data — and laboratory results provide that data.”

Houston geothermal startup secures $97M Series B for next-gen power

fresh funding

Houston-based geothermal energy startup Sage Geosystems has closed its Series B fundraising round and plans to use the money to launch its first commercial next-generation geothermal power generation facility.

Ormat Technologies and Carbon Direct Capital co-led the $97 million round, according to a press release from Sage. Existing investors Exa, Nabors, alfa8, Arch Meredith, Abilene Partners, Cubit Capital and Ignis H2 Energy also participated, as well as new investors SiteGround Capital and The UC Berkeley Foundation’s Climate Solutions Fund.

The new geothermal power generation facility will be located at one of Ormat Technologies' existing power plants. The Nevada-based company has geothermal power projects in the U.S. and numerous other countries around the world. The facility will use Sage’s proprietary pressure geothermal technology, which extracts geothermal heat energy from hot dry rock, an abundant geothermal resource.

“Pressure geothermal is designed to be commercial, scalable and deployable almost anywhere,” Cindy Taff, CEO of Sage Geosystems, said in the news release. “This Series B allows us to prove that at commercial scale, reflecting strong conviction from partners who understand both the urgency of energy demand and the criticality of firm power.”

Sage reports that partnering with the Ormat facility will allow it to market and scale up its pressure geothermal technology at a faster rate.

“This investment builds on the strong foundation we’ve established through our commercial agreement and reinforces Ormat’s commitment to accelerating geothermal development,” Doron Blachar, CEO of Ormat Technologies, added in the release. “Sage’s technical expertise and innovative approach are well aligned with Ormat’s strategy to move faster from concept to commercialization. We’re pleased to take this natural next step in a partnership we believe strongly in.”

In 2024, Sage agreed to deliver up to 150 megawatts of new geothermal baseload power to Meta, the parent company of Facebook. At the time, the companies reported that the project's first phase would aim to be operating in 2027.

The company also raised a $17 million Series A, led by Chesapeake Energy Corp., in 2024.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

10+ can't-miss Houston business and innovation events in February

where to be

Editor's note: February may be short, but its event calendar isn’t. From recurring monthly favorites to the return of annual celebrations and summits, here's what not to miss and how to register. Please note: this article may be updated to include additional event listings.

Feb. 2 — Entrepreneurship Roundtable with OPEN

Join founders, builders and innovators as they explore what it takes to create, scale and sustain meaningful ventures. This event, hosted by Open Houston, will be moderated by Faisal Bhutto, president and CEO of Houston-based end-to-end IT and cybersecurity company Alykas.

This event is Monday, Feb. 2, from 11 a.m.-1 p.m. at the Ion. Register here.

Feb. 3 — Tech+Tequila Talk: Tax Equity: Aligning Incentives for Founders, Investors & Philanthropy

Hear from guest speaker Cesar de la Cerda, founder and CIO of EnvisionVest, at the latest installment of Tech and Tequila Talk. The event will focus on using the tax code as a powerful fundraising tool.

This event takes place Tuesday, Feb. 3, from 5-7 p.m. at the Ion. Register here.

Feb. 5 — Ion Block Party Mardi Gras

Let the good times roll while networking with potential collaborators, mentors and investors at the Ion. Food and drink will be available, and the Ion will provide drink tickets for one free drink at Second Draught upon check-in.

This event is Thursday, Feb. 5, from 4-7 p.m. at the Ion. Register here.

Feb. 10 — Mercury Fund Day at the Ion

The Ion and Houston's Mercury Fund will host this special event, previously known as Software Day. The event will feature a panel that dives into how Mercury is pushing the boundaries of what’s possible with agentic AI and blockchain. A select group of early-stage software startups will also participate in office hours before the panel. Afterwards, all attendees can network during happy hour at Second Draught.

This event is Tuesday, Feb. 10, from 3:30-7:30 p.m. Register here.

Feb. 11-12 – In-Space Physical AI Workshop

Rice Nexus is bringing together industry leaders, government agencies and academia to explore the cutting edge of AI in space exploration. Matt Ondler, president of Aegis Aerospace, will present the keynote address. Other industry leaders from NASA Johnson Space Center, Intuitive Machines, Microsoft and Rice University and other organizations will participate. The event will close with the Inaugural Space Galette Reception hosted by the Consulate General of France in Houston and the Rice Space Institute.

This event begins Wednesday, Feb. 11, at the Ion. Register here.

Feb. 12 — State of the City

Houston First Corporation and the Greater Houston Partnership will host Mayor John Whitmire’s State of the City luncheon. Whitmire will share an update on his administration’s progress since taking office and highlight his top priorities that will continue to elevate Houston and its economy.

This event is Thursday, Feb. 12, from 11 a.m.-1:30 p.m. at the Hilton Americas-Houston. Register here.

Feb. 12 — Positioning Houston as the Brain Capital of the World

David Gow, CEO of the Center for Houston's Future, will present "Positioning Houston as the Brain Capital of the World" at the University of Houston Honors College Leadership Forum. Gow will share how Project Metis aims to establish Houston as a global hub for brain health research, innovation and economic development.

This event is Thursday, Feb. 12, from 7:30-9:30 a.m. at The Junior League of Houston. Register here.

Feb. 13 — From Research to Enterprise: Immigration & Innovation

Innov8 Hub will host an in-person seminar as part of its Startup Resources Series, focused on the intersection of immigration law, entrepreneurship and technology commercialization. The session will feature guest speakers Mario Cantu, Shilpa Ghurye and Vikesh Patel of KM&D PLLC, who will share insights for founders and innovators navigating legal pathways while building and scaling technology-driven ventures.

The event is Friday, Feb. 13, from 1-2 p.m. at the Innovation Center at UH Technology Bridge, Building 4. Register here.

Feb. 18-20 — TMC AI Summit

UTHealth Houston and Texas Children’s Hospital are bringing back the TMC AI Summit for its third year. This event is focused on translating advanced AI innovations into practical, real-world solutions for the biomedical and healthcare industries. It will be broken up into three tracks and will feature poster and oral presentations, workshops and tutorials, industry talks and student research showcases.

The event begins Wednesday, Feb. 18, at the Duncan Neurological Research Institute. Register here.

Feb. 26 — Transition on Tap

Greentown Labs’ signature networking event returns in February to foster conversations and connections within Houston's climate and energy transition ecosystem. Entrepreneurs, investors, students, philanthropists and more are invited to attend, meet colleagues, discuss solutions and engage with the growing community.

The event begins Monday, Feb. 26, from 5:30-7:30 p.m. at Greentown Labs. Register here.

Feb. 26 — NASA Tech Talk

Every fourth Thursday of the month, NASA experts, including longtime engineer Montgomery Goforth, present on technology development challenges NASA’s Johnson Space Center and the larger aerospace community are facing, and how they can be leveraged by Houston’s innovation community. Stick around after for drinks and networking at Second Draught.

This event is Thursday, Feb. 26, from 6-7 p.m. at the Ion. Register here.

View All Listings